Engineered to target the cancer,
not the patient
BiVictriX is building a novel pipeline of next generation therapeutics that have superior cancer selectivity. By significantly reducing harmful side-effects, we aim to vastly improve the safe dose of therapy patients can withstand; improving the overall effectiveness of the treatment at eradicating the cancer.
Our approach relies on utilising our proprietary library of ‘cancer-specific twin antigen fingerprints’ which are uniquely expressed on the cancer, allowing them to be targeted while leaving healthy cells alone.
By applying this science, we created our Bi-Cygni® therapeutics
